Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02446236
Title Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hackensack University Medical Center
Indications

mantle cell lymphoma

Therapies

Ibrutinib + Lenalidomide + Rituximab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
The Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field